A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
Status:
Terminated
Trial end date:
2020-02-24
Target enrollment:
Participant gender:
Summary
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled,
parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamic effects of RVT-1201 in patients with pulmonary arterial hypertension (PAH).